

## Drug Discovery 2018 Learning Paths: Your Learning Experience Starts Here

As an Early Career Professional, with 50 free to attend talks, workshops and technical trainings, Drug Discovery 2018 is the place to learn about your topic of interest in life science research. Choose from the learning paths below, to follow your area of research and plan your Drug Discovery experience.

Non-Small Molecule Drug Discovery	How Working With CRO's Can Help You Discover Drugs	Innovative Technologies And Techniques	How Collaborative Working Is Tackling Challenging Diseases	Novel Targets And Molecules
<b>Platinum Suite 1:</b> 9 Oct 11:00	<b>Platinum Suite 1:</b> 9 Oct 16:00	<b>Platinum Suite 2:</b> 9 Oct 11:45	<b>Platinum Suite 3:</b> 9 Oct 11:00	<b>Platinum Suite 4:</b> 9 Oct 11:30
<i>Highly potent and selective tumour targeting bicyclic peptides - a novel approach to cancer therapy</i> <b>Gemma Mudd</b> (Bicycle Therapeutics)	<i>Capture Compound® Mass Spectrometry: On- and Off-Target Deconvolution</i> <b>Andrew Cridland</b> (Charles River)	<i>Cellular thermal shift assays in high throughput: a 1536-well cellular target engagement assay for drug discovery</i> <b>Lorena Kallal</b> (GlaxoSmithKline)	<i>Using AI to accelerate combinations drug discovery for rare diseases</i> <b>Michale Bouskila-Chubb</b> (Healx Ltd)	<i>Neuro-immune interactions and novel targets for chronic pain</i> <b>Marzia Malcangio</b> (Kings College London)
<b>Platinum Suite 1:</b> 9 Oct: 11:45	<b>Platinum Suite 4:</b> 10 Oct 11:30	<b>Platinum Suite 2:</b> 9 Oct 16:00	<b>Platinum Suite 3:</b> 10 Oct: 14:00	<b>Platinum Suite 1:</b> 9 Oct 14:00
<i>How the chemical design and synthesis of linkers used in antibody drug conjugates drives the success of ADC drug development.</i> <b>Mark Frigerio</b> (Abzena)	<i>The Centaur Chemist: AI in drug design</i> <b>Andrew Hopkins</b> (ExScientia)	<i>Organoids: Predicting clinical responses in an in vitro model</i> <b>Robert Vries</b> (Hubrecht Organoid technology)	<i>The Dementia Discovery Fund – a novel, collaborative venture</i> <b>Laurence Barker</b> (Dementia Discovery Fund)	<i>Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables transient target engagement for the treatment of haematological malignancies.</i> <b>Bernard Barlaam</b> (AstraZeneca)
<b>Platinum Suite 2:</b> 10 Oct: 11:30	<b>Platinum Suite 3:</b> 10 Oct: 14:30	<b>Platinum Suite 1:</b> 9 Oct: 16:30	<b>Platinum Suite 3:</b> 10 Oct: 15:45	<b>Platinum Suite 3:</b> 9 Oct: 14:00
<i>Patient-Focused Bispecific Target Discovery by High Throughput Functional Screening</i> <b>Ahmad Kamal</b> (UCB Celltech)	<i>Building bridges: An academic-industry exercise</i> <b>Mark Slack</b> (Evotec)	<i>Using PROTACs as probes to study intracellular target engagement against proteins with unknown function</i> <b>Matthew Cheeseman</b> (Institute of Cancer Research)	<i>Apollo Therapeutics - a novel, collaborative drug discovery model</i> <b>Richard Butt</b> (Apollo Therapeutics)	<i>An academic entrepreneur's thoughts about drug discovery where reductionism bumps up against biological complexity and drug promiscuity: generating meaningful targets</i> <b>Steven Zimmer</b> (MitoDys Therapeutics)
<b>Platinum Suite 1:</b> 10 Oct: 14:00	<b>Platinum Suite 1:</b> 10 Oct: 15:15	<b>Platinum Suite 1:</b> 10 Oct: 11:30		<b>Platinum Suite 4:</b> 9 Oct: 14:30
<i>Biophysical and Biochemical assay technologies for antibody discovery, and considerations for their uses.</i> <b>Martin Redhead</b> (UCB)	<i>Smarter IDO inhibitor profiling by incorporating biophysical, biochemical and cellular target engagement approaches</i> <b>Scott Pollack</b> (Sygnature Discovery)	<i>Application of Acoustic Mist Ionization Mass Spectrometry (AMI-MS) for the Development of Kinase Assays</i> <b>Deepika Srivastava</b> (AstraZeneca)		<i>Natural and engineered genetics for new pain target discovery</i> <b>Alex Gutteridge</b> (GlaxoSmithKline)
<b>Platinum Suite 2:</b> 10 Oct: 15:15		<b>Platinum Suite 2:</b> 10 Oct: 14:30		<b>Platinum Suite 3:</b> 9 Oct: 16:30
<i>Targeting Solid Tumours with Antibody Fragment Drug Conjugates</i> <b>Bryan Edwards</b> (Antikor Biopharma)		<i>Single domain antibody platform for delivery of biologics across the blood brain barrier</i> <b>Pawel Stocki</b> (Ossianix Inc)		<i>Combination drugs for safe treatment of children with rare cancers</i> <b>David Brown</b> (Healx Ltd)
		<b>Platinum Suite 4:</b> 10 Oct: 15:15		<b>Platinum Suite 2:</b> 10 Oct: 15:45
		<i>Artificial Intelligence in Drug Discovery from a Medicinal Chemistry Viewpoint</i> <b>Ola Engkvist</b> (AstraZeneca)		<i>The Discovery of Anti-BCMA: One Antibody, Two Flavours</i> <b>Stephen Ashman</b> (GlaxoSmithKline)